In the News

By: Michael Monostra In adults living with HIV, those with three or more metabolic risk factors had a higher risk for developing new-onset diabetes than those […]

Data from the REPRIEVE trial suggest there is only a minimal increased risk of diabetes with statins among people with HIV, and in specific, limited groups […]

By John W. McEvoy and Cian Mangan The potential of high-sensitivity cardiac troponin (hs-cTn) assays to augment cardiovascular disease (CVD) prediction in primary prevention has long been an […]

People with HIV who took the antiretroviral drug abacavir (Ziagen) had an increased risk of major adverse cardiovascular events (MACE), according to an exploratory analysis of […]

Current or previous use of the antiretroviral drug (ARV) abacavir was associated with an elevated risk of major adverse cardiovascular events (MACE) in people with HIV, […]

ACTG, a global clinical trials network focused on HIV and other infectious diseases, will present an exploratory analysis from the REPRIEVE trial demonstrating that former and […]

By Alicia Banks, Duke Global Health Institute As Gerald S. Bloomfield, M.D., saw heart patients in Kenya over the past decade, he knew that cardiovascular disease […]

By Ronak Rajani, Roberta Lima Brum, and Vitaliy Androshchuk HIV affects approximately 45 million people worldwide, making it a major ongoing public health challenge. Although antiretroviral […]

By Kathleen V. Fitch, Marissa Diggs, and Steve Grinspoon Due to the remarkable strides in the management and support of PWH, life expectancy now almost parallels […]

By Keith Alcorn The REPRIEVE study of pitavastatin for prevention of cardiovascular disease showed that statins reduced the risk of major cardiovascular events such as heart attack […]

On Tuesday at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI), HIV.gov spoke with NIH’s Dr. Carl Dieffenbach about research on common health complications of […]

The elevated cardiovascular disease risk among people with HIV is even greater than predicted by a standard risk calculator in several groups, including Black people and […]

The Department of Health and Human Services Guidelines Panel for the Use of Antiretroviral Agents in Adults and Adolescents with HIV (the Panel) has developed recommendations […]

By David Alain Wohl, MD While it’s not new, injected, implanted, or even prohibitively expensive, it is the medication studied in the most important HIV-related clinical […]

By Rajesh T. Gandhi The editors present their choices of the most important articles from the year. Read the full article here.

By Liz Highleyman The British HIV Association (BHIVA) now recommends that all people living with HIV who are ages 40 and older should be offered a statin […]

November 21, 2023 In cohort studies, compared to the general population or controls without HIV, people living with HIV are at greater risk of atherosclerotic cardiovascular […]

November 29, 2023 December 1 marks the 35th commemoration of World AIDS Day, an annual event that reminds us that HIV and HIV-related stigma remain public […]

By Iulia Filip The puzzle of cardiovascular (CV) risk reduction in people with HIV (PWH) is a hard one to solve in the absence of CV risk […]

By Erik Swain Pitavastatin lowered noncalcified plaque volume and reduced risk for plaque progression compared with placebo in patients with HIV at low to moderate risk […]

By Linda Searing Although people living with HIV have a greatly increased risk for cardiovascular issues, such as blocked arteries, heart attacks and stroke, new research has found […]

By Benjamin Ryan A recent study showed that a statin drug significantly lowered the risk of heart attacks and strokes among middle-aged and older people with […]

People living with HIV have increased risk for cardiovascular disease (and other diseases of aging) earlier in life than those without HIV. In this episode of […]

By Liz Highleyman Findings from the landmark REPRIEVE trial, which tested a daily statin medication for people living with HIV, were presented on Monday at the 12th […]

By Rajesh T. Gandhi A randomized trial demonstrates that even those PWH at low-to-moderate risk for cardiovascular disease benefit from starting pitavastatin. Read the full article […]

By Paul Sax The biggest news this week at the 12th IAS Conference on HIV Science here in Brisbane, Australia, was the results of REPRIEVE, a large […]

By Larry Buhl A triumphant mood was evident at a session of the 12th International AIDS Society (IAS) Conference on HIV Science during which a panel […]

By Liz Highleyman REPRIEVE trial finds pitavastatin reduced the risk of heart attack, stroke and other major cardiovascular events by 35%. Read the full article here.

By Cara Murez Heart disease is a high risk for people with HIV, but a new study finds that taking statins significantly reduces the risk of […]

By Bianca Nogrady “I think the data are suggesting that it’s certainly in part due to the reduction in LDL — that is very important — […]

By Ed Susman The cholesterol-lowering agent pitavastatin (Livalo) as primary prevention reduced the risk of major adverse cardiovascular events (MACE) among people living with HIV, the […]

By Deborah Balthazar A statin a day reduces the risk of heart disease in younger people living with HIV, according to a new study published Sunday in the […]

By Liz Highleyman A widely used statin medication reduced the risk of heart attacks, strokes and other cardiovascular events when given to people with HIV who […]

By Noah Brown The risk of cardiovascular diseases, including myocardial infarction and stroke, has been shown to be roughly twice as high in people living with […]

By Giri Viswanathan Scientists have long known that people living with HIV face a higher risk of heart disease. The statin drug pitavastatin, however, might offer a […]

A National Institute of Health-supported study found that statins, a class of cholesterol-lowering medications, may offset the high risk of cardiovascular disease in people living with […]

By Priya Venkatesan The REPRIEVE trial has shown a benefit of statins in reducing the risk of cardiovascular events in people living with HIV, but many […]

By Emily Harris People with HIV and a low to moderate traditional risk of cardiovascular disease who took a daily 4-mg dose of pitavastatin reduced their risk […]

By Liz Highleyman Large trial finds that pitavastatin lowered the risk for major cardiovascular events by 35%. Read the full article here.

By Megan Brooks An international clinical trial testing statin therapy for primary cardiovascular prevention in people living with HIV has been stopped early due to strong […]

By Shelley Wood HIV is merely a “risk modifier” in current guidelines; these results pave the way for a new primary-prevention indication for statins. Read the […]

By Barbara Jungwirth People living with HIV (PLWH) taking integrase strand transfer inhibitors (INSTIs) gained more weight during the first two years of that regimen than […]

Press Release from Massachusetts General Hospital Read the full feature here.

In Massachusetts General Hospital Advances in Motion Read the full feature here.

In Massachusetts General Hospital Snapshot of Science Read the full newsletter here.

By Heather Boerner Read the full article here.

By Barbara Jungwirth and Myles Helfand Read the full article here.

By Liz Highleyman Read the full article here.

By Caitlyn Stulpin Read the full article here.

Rates are similar to the general population but vary across geographic regions. Read the full article here.

The REPRIEVE study finds that many younger, asymptomatic adults with HIV have levels of plaque that persist despite low traditional risk of ASCVD. Caitlan Rossi, MedPage […]

In his #WorldAIDSDay statement, Dr. Fauci highlights how far we have come, how far we have yet to go, and acknowledges the important work of the […]

White men and smokers are more likely to have arterial plaque despite low cardiovascular risk scores. Heather Boerner | POZ Read the full article here.

Nearly half of the participants (49%) had plaque in their arteries. ACTG Read the full article here.

Researchers ID condition with potential CVD implications. Randy YoungMGH News and Public Affairs Read the full article from HMS here.

The REPRIEVE study, which is primarily looking at a statin’s effect on cardiovascular disease, is shedding light on many other mysteries. Benjamin RyanEditor at Large, POZ […]

Initial data from a large NIH-supported clinical trial offer a detailed look at the health status of people aging with HIV around the world. With 7,770 […]

The impact and prevalence of heart disease and other critical comorbidities on an aging global population with human immunodeficiency virus (HIV) have emerged from a suite […]

People living with HIV are developing heart disease at twice the rate of the general population, and Prism Health and Harvard Medical School want to know […]

An international clinical trial, which is looking for effective ways to prevent heart disease in those living with HIV, has hit 7,000 participants. “It’s a major […]

HIV-related heart disease is a leading cause of death among people living with HIV — even when they are on consistent, effective HIV treatment. Researchers are […]

Today marks not just a time to exchange valentines and chocolates, but also the midpoint of American Heart Month(link is external). Did you know people living with […]

Throughout history, women have been excluded from clinical research studies, resulting in a dearth of knowledge about the effect that drugs might have on different sexes. […]

In the first World AIDS Day in 1988, the outlook was bleak for people living with this strange, new, and deadly disease. Few could imagine the […]

Today marks the 10th National HIV/AIDS and Aging Awareness Day. This annual observance brings attention to the unique social and health-related challenges of older people living […]

As people living with HIV grow older, heart disease is emerging as a major public health problem despite effective treatments that suppress the virus and extend […]

Cardiovascular disease, including atherosclerosis and atherosclerosis-associated complications, is an increasing cause of morbidity and mortality in human immunodeficiency virus (HIV) patients in the post-antiretroviral therapy era. […]

People infected with HIV can now live long, healthy lives — so long as they don’t have a heart attack. Cardiovascular problems among HIV patients are emerging as […]

Stemming from the INTREPID Trial, three recently published papers give credence to pitavastatin’s ability to lower cholesterol and dampen inflammation in people living with HIV.

For years Medical researchers, government agencies and health institutes have been looking at ways to improve health outcomes of individuals living with HIV/AIDS. With the advent […]

There is a saying in South Africa: Wathint’ abafazi, wathint’ imbokodo. You strike the women, you strike the rock. On International Women’s Day, we want to […]

A US-funded study is recruiting South Africans to help find a way to prevent heart disease among HIV-positive people. Someone with HIV can have more than […]

February is heart health month, a perfect time to focus our attention on an important area of concern in the HIV community: cardiovascular health. People living […]

Antiretroviral therapy (ART) has transformed HIV infection from an almost-always fatal disease to what is now a manageable, chronic health condition. Today, a person diagnosed with […]

The people researching cardiovascular disease in HIV have quite the challenge.Because when you think about it for a second, we HIV treaters are a pretty spoiled bunch […]

People with HIV seldom die of AIDS-related opportunistic infections anymore. Thanks to modern medicine called highly active antiretroviral therapy, or HAART, many people diagnosed with HIV […]

February is American Heart Month, and traditionally a time when organizations such as the American Heart Association ramp up initiatives to promote awareness of heart disease. […]

HIV is linked to a higher heart disease risk. Research suggests statins can help. But definitive proof likely won’t come for another three years. Even when […]

Your 50 Year-old, female, HIV-positive patient, presents for a follow-up visit. She has heard that the risk of cardiovascular disease is increased among people living with […]

This year, the world marked the 35th anniversary of the first published reports of what would come to be known as HIV/AIDS. This disease has wrought […]

“I had no idea that since I have HIV, I may be twice as likely to have a heart event compared to the general population,” said Frank […]

Earlier this month, AVAC hosted a webinar to explain and explore the complex issues of hormonal contraceptives and HIV risk in light of a new analysis that is generating […]

Historically, understanding a woman’s unique biology and developing optimal interventions for women has been somewhat of a blind spot for medical research. For much of the […]

Research shows that women are often underrepresented in HIV clinical trials. In fact, astudy recently published in the Journal of Acquired Immune Deficiency Syndromes found that less […]

HIV-positive men and women can now live longer than ever before. A 2013 study found that a newly diagnosed 20-year-old on effective antiretroviral therapy (ART) can […]

Human immunodeficiency virus infection is no longer the death sentence it was 30 years ago, but HIV-infected adults may face a new health hurdle – heart […]

The REPRIEVE trial, which will test a sort of “PrEP for heart disease” among 6,500 people with HIV at sites around the world, has already enrolled […]

Researchers at two area universities are among those participating in a nationwide clinical trial focused on HIV-related cardiovascular disease. University of Illinois at Chicago and Northwestern […]

Several Boston-area doctors will serve as primary investigators in a worldwide study on heart disease among HIV/AIDS patients — just one deadly upshot of an illness […]

Call it a PrEP to protect against heart disease in people with HIV.A large, multi-site clinical trial dubbed REPRIEVE has begun enrolling across the U.S. and […]

Over the course of their careers, many clinicians have seen HIV/AIDS progress from extremely high short-term mortality to chronic, long-term disease management. As HIV patients are […]

Leadership from REPRIEVE: Randomized Trial to Prevent Vascular Events in HIV, would like to recognize World AIDS Day as a time to remember those we have lost to HIV/AIDS and also recognize the progress that has been made to help people with HIV live longer, healthier lives.

As HIV-positive people continue living longer due to highly active antiretroviral therapy, cardiovascular disease has become a growing concern.  According to the National Institute of Allergy and […]

HIV infection is associated with increased cardiovascular disease (CVD), and increased rates of myocardial infarction and stroke have been observed in HIV-infected individuals. After traditional risk […]

HIV raises the risk of heart disease. What can you do to lower that risk?People with HIV are at a greater risk for heart disease than […]

Antiretroviral therapy (ART) has been a lifeline for untold numbers of patients with HIV. But as mounting evidence shows the infection may increase their risk of […]

JAMA article highlights REPRIEVE trial for studying ways to prevent HIV-Related Heart Disease! Individuals living with HIV are at increased risk of heart disease.

REPRIEVE was recently featured online in POZ. Click here to read more!

Washington University's participation in the REPRIEVE trial is featured in the St. Louis Post-Dispatch!